Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate

Autor: Joan Manel Gasent Blesa, Enrique Grande Pulido, Juan Laforga Canales, Vicente Alberola Candel

Publikováno v: Case Reports in Oncology, Vol 2, Iss 3, Pp 234-241 (2009)

Patients with advanced germ cell tumors can be cured with cisplatin-based chemotherapy, but the outcome remains unsatisfactory for patients with relapsed disease, including those patients with refractory disease after bone marrow transplantation. Tar

Externí odkaz: https://doaj.org/article/7e327867b0174d708411c07ea8988cc1

Old and New Insights in the Treatment of Thyroid Carcinoma

Autor: Joan Manel Gasent Blesa, Enrique Grande Pulido, Mariano Provencio Pulla, Vicente Alberola Candel, Juan Bautista Laforga Canales, Miguel Grimalt Arrom, Patricia Martin Rico

Publikováno v: Journal of Thyroid Research, Vol 2010 (2010)

Thyroid cancer is the endocrine tumor that bears the highest incidence with 33 550 new cases per year. It bears an excellent prognosis with a mortality of 1530 patients per year (Jemal et al.; 2007). We have been treating patients with thyroid carcin

Externí odkaz: https://doaj.org/article/d5380ca015dd423497c625663c2fccbb

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab

Autor: Mariano Provencio Pulla, Miguel Peris Godoy, José Miguel Sempere Ortells, María Fonfría Esparcia, Vicente Alberola Candel, Adrián Munilla Das, José Luis Sánchez, Balbino Mancheño Magán, Joan Manel Gasent Blesa, Sara Blasco Mollá, Juan Laforga Canales

Publikováno v: Case Reports in Oncology, Vol 5, Iss 3, Pp 676-681 (2012)
RUA. Repositorio Institucional de la Universidad de Alicante
Universidad de Alicante (UA)
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Case Reports in Oncology

Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15d796e56c5d9e9ed8cb5088964e75c8
http://www.karger.com/Article/FullText/341852

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

Autor: Mariano Provencio Pulla, Juan Jesús Cruz Hernández, Agustí Barnadas i Molins, Ma. Dolores Isla Casado, Ana Ma. Casas Fernández de Tejerina, Manuel González Barón, Eduardo Díaz Rubio García, Carlos Camps Herrero, Miguel Martín Jiménez, Vicente Alberola Candel, Manuel Constenla Figueiras, Alfredo Carrato Mena, Joan Carulla Torrent, Joaquin Gavilá Gregori, Jaime Sanz Ortiz, Pere Gascón Vilaplana, Emilio Alba Conejo, Javier Cassinello Espinosa, César A. Rodríguez Sánchez, Bartomeu Massuti Sureda, Ramon Colomer

Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e733bba1d7b8831aa3f7aa21cf2b6f
https://doi.org/10.1007/s12094-009-0435-6

Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy

Autor: Rafael Rosell, Felipe Cardenal, Manuel Domine, Bartomeu Massuti, Inmaculada Maeztu, A. Ramos, Antonio Arellano, Pilar Garrido, Vicente Alberola

Publikováno v: Clinical Lung Cancer. 10:180-186

The aim of this study was to analyze prognostic variables associated with long-term survival in patients with stage III non-small-cell lung cancer enrolled in a Spanish Lung Cancer Group (SLCG) phase II trial.Between May 2001 and June 2006, 139 patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a3f46572b8dbd638156f1e98515ad2
https://doi.org/10.3816/clc.2009.n.025